In sharp rebuke to Trump Administration, HHS notice ending Unapproved Drugs Initiative is withdrawn

Published date01 June 2021
Subject MatterFDA,Life Sciences,Prescription Drugs,Regulatory Standards,Regulatory Reform,FDA Approval,Pharmaceutical Industry,Department of Health and Human Services (HHS)
AuthorJames Johnson,Robert Church,David Horowitz
Law FirmHogan Lovells

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT